Colorectal Cancer
Conditions
Interventions
Test group:68Ga-NODAGA-SNA009 and 18F-FDG PET-CT imaging
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years (inclusive). 2. Subjects with capacity for civil conduct who voluntarily participate in this clinical trial and provide written informed consent. 3. Patients with confirmed diagnosis of colorectal cancer. 4. Have not received prior following treatments for the target tumor: tumor resection/radical surgery (excluding diagnostic biopsy), radiotherapy (including brachytherapy), systemic anti-tumor drugs (e.g., chemotherapy, small molecule targeted therapy, monoclonal antibody drugs), or any other investigational therapy from a clinical study. 5. Results from endoscopic/CT/MRI/PET-CT examinations within the past 1 month (if available). 6. Pathological test results within the past 1 year.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with other concurrent malignancies. 2. Patients with uncontrolled severe infection, or those accompanied by other severe underlying diseases. 3. Patients with an expected life expectancy of = 3 months. 4. Pregnant or lactating patients, and patients of childbearing potential who refuse to adopt adequate contraceptive measures during the trial period. 5. Patients deemed by the investigator as unsuitable for participation in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medication Safety;Radiation Absorption Dose Characteristics;Biodistribution Profile;PET Imaging Characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between PET imaging and GPA33 expression levels as measured by immunohistochemistry (IHC);Diagnostic Efficacy; | — |
Countries
China
Contacts
Public ContactDai Dong
Tianjin Medical University Cancer Institute and Hospital
Outcome results
None listed